⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MLTX News
MoonLake Immunotherapeutics Class A Ordinary Shares
Form 8-K
sec.gov
MLTX
Form 8-K
sec.gov
MLTX
Form 8-K
sec.gov
MLTX
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
globenewswire.com
MLTX
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
globenewswire.com
MLTX
Form 8-K
sec.gov
MLTX
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
globenewswire.com
MLTX
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
globenewswire.com
IMA
MLTX
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
globenewswire.com
MLTX
Morning Market Pulse: From Orbit to Biomaterials, Innovation Drives the Tape
globenewswire.com
FLYX
ACON
MLTX